Earning Preview: LIVZON PHARMA Q2 revenue is expected to decrease by 5.79%, and institutional views are constructive

Earnings Agent08-14

Abstract

LIVZON PHARMA will release its Q2 2026 results post-Market on August 21, 2026. Consensus points to softer year-over-year revenue with resilient margins and stable earnings per share, while investor focus is on the mix shift within core prescription drugs and cost control.

Market Forecast

For the current quarter, market projections indicate revenue of 2.95 billion RMB, representing a year-over-year decrease of 5.79%, EBIT of 697.85 million RMB with a 1.12% year-over-year increase, and EPS of 0.64 with a 12.28% year-over-year increase. The prior quarter’s performance implies gross profit margin around the mid-60s and net profit margin around one-fifth of revenue, suggesting a margin profile that could remain relatively stable year over year. The main business is pharmaceutical manufacturing, where the mix remains dominated by prescription formulations; revenue is estimated at 2.95 billion RMB with the company signaling improved profitability from product upgrades. The most promising segment is core pharmaceutical manufacturing, with revenue of 2.95 billion RMB and a forecast year-over-year decline of 5.79% mitigated by margin resilience due to product and cost optimization.

Last Quarter Review

In the previous quarter, LIVZON PHARMA reported revenue of 2.87 billion RMB, a gross profit margin of 65.87%, GAAP net profit attributable to the parent company of 577.00 million RMB, a net profit margin of 20.09%, and adjusted EPS of 0.65, with year-over-year changes of -9.74% for revenue, -5.42% for EBIT, and -8.45% for EPS. Quarter-on-quarter net profit attributable to the parent grew by 114.35%, reflecting strong sequential recovery from prior softness. Main business highlights center on pharmaceutical manufacturing, with revenue of 2.87 billion RMB and year-over-year decline of 9.74% amid ongoing pricing normalization and volume-based procurement pressures.

Current Quarter Outlook

Pharmaceutical Manufacturing

The core pharmaceutical manufacturing business is expected to generate approximately 2.95 billion RMB in revenue this quarter, down 5.79% year over year. Despite the revenue headwind, margin resilience is supported by a stable gross profit structure and sustained cost management, referencing last quarter’s 65.87% gross margin and 20.09% net margin baseline. Product portfolio refinements, including the relative focus on higher-value therapeutics, should help defend profitability even as top-line growth softens.

Operationally, pricing dynamics under volume-based procurement continue to be a primary factor influencing revenue, but LIVZON PHARMA’s ability to optimize manufacturing costs and adjust product mix can offset part of the pressure. Sequential comparisons are likely to show steadier results following the prior quarter’s rebound in net profit, aided by operational efficiencies. Inventory discipline and targeted commercialization efforts within hospital channels remain central to sustaining margins.

Growth Potential Within Core Portfolio

The most promising area remains within the company’s core pharmaceutical portfolio, where incremental contributions from upgraded formulations and improved commercialization efficiency can support earnings quality. Even with a forecast revenue decline, the expected 12.28% year-over-year improvement in EPS suggests enhanced cost structure and operating leverage. With EBIT forecast at 697.85 million RMB and a 1.12% year-over-year rise, the profit engine appears positioned to balance pricing pressure with productivity gains.

Key levers include procurement strategy optimization, supply chain cost reductions, and disciplined expense control in sales and administration. These measures are consistent with the margin durability observed last quarter and can continue to sustain profitability this quarter. Continued focus on therapeutic categories with favorable reimbursement and clinical demand should help stabilize volume trends.

Stock Price Drivers This Quarter

Near-term stock performance will hinge on the interplay between revenue trajectory and margin preservation. Investors are likely to scrutinize whether the company can maintain gross margins near the prior quarter’s 65.87% level while delivering the projected EPS uplift to 0.64. Any deviations in EBIT versus the 697.85 million RMB forecast could drive sentiment, particularly if revenue softness worsens or cost efficiencies underperform.

Additionally, clarity on product mix changes and procurement outcomes will be important. Signs of stabilization in pricing or evidence of successful margin defense through cost reduction could support confidence. Conversely, if revenue declines exceed expectations without corresponding margin support, market reaction may turn cautious.

Analyst Opinions

Analyst previews collected over the period indicate a majority constructive stance, citing the company’s capacity to sustain margins and achieve EPS growth despite top-line pressure. Institutions highlight the potential for stable EBIT supported by cost optimization and product mix improvements, with the consensus viewing the quarter as a test of margin resilience rather than a growth inflection. The prevailing view expects the company to meet or slightly exceed EPS forecasts while revenue modestly underperforms, maintaining confidence in earnings durability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.